Evidence map›Paper›PMID 36609374›Full record

ArticleJournal of nanobiotechnology2023

PDGFB-targeted functional MRI nanoswitch for activatable T

Ya'nan Zhang, Lu Liu, Wenling Li, Caiyun Zhang, Tianwei Song, Peng Wang, Daxi Sun, Xiaodan Huang, Xia Qin, Lang Ran and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Mn-Based MRI Contrast Agents: An Overview.Molecules (Basel, Switzerland) · 2023
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Ya'nan ZhangSchool of Medical Imaging, Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai, 264003, People's Republic of China.
Lu LiuSchool of Medical Imaging, Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai, 264003, People's Republic of China.
Wenling LiSchool of Medical Imaging, Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai, 264003, People's Republic of China.
Caiyun ZhangSchool of Medical Imaging, Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai, 264003, People's Republic of China.
Tianwei SongSchool of Medical Imaging, Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai, 264003, People's Republic of China.
Peng WangSchool of Medical Imaging, Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai, 264003, People's Republic of China.
Daxi SunSchool of Medical Imaging, Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai, 264003, People's Republic of China.
Xiaodan HuangSchool of Medical Imaging, Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai, 264003, People's Republic of China.
Xia QinSchool of Medical Imaging, Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai, 264003, People's Republic of China.
Lang RanSchool of Medical Imaging, Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai, 264003, People's Republic of China.
Geng TianSchool of Medical Imaging, Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai, 264003, People's Republic of China. tiangeng@bzmc.edu.cn.
Junchao QianHefei Cancer Hospital, Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, People's Republic of China. qianjunchao@hmfl.ac.cn.
Guilong ZhangSchool of Medical Imaging, Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai, 264003, People's Republic of China. glzhang@bzmc.edu.cn.
Binzhou University · CNBinzhou Medical University · CNHefei Institutes of Physical Science · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As one of the most significant imaging modalities currently available, magnetic resonance imaging (MRI) has been extensively utilized for clinically accurate cancer diagnosis. However, low signal-to-noise ratio (SNR) and low specificity for tumors continue to pose significant challenges. Inspired by the distance-dependent magnetic resonance tuning (MRET) phenomenon, the tumor microenvironment (TME)-activated off-on T

Indexed as

Contrast MediaNeoplasmsHumansMagnetic Resonance ImagingMaleProto-Oncogene Proteins c-sisSilicon DioxideTumor MicroenvironmentContrast MediaProto-Oncogene Proteins c-sisSilicon DioxideDual-mode contrast agentMagnetic resonance imagingSNRTME-activated nanoswitchTumor diagnosis

Identifiers

PMID36609374
PMCPMC9824934
OpenAlexW4313650122

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.